Gonadorelin vs Melanotan II

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin dosage in TRT support contexts: in men on testosterone replacement therapy, gonadorelin is commonly used off-label to maintain testicular function and endogenous testosterone production capacity. Subcutaneous doses of 100 mcg administered twice weekly are frequently cited in TRT clinical protocols for this purpose — injected at a pulsatile rather than continuous delivery pattern to preserve LH/FSH signaling. This application requires physician supervision due to the dose-timing sensitivity; the paradoxical suppression from continuous dosing is a clinically important consideration that distinguishes gonadorelin from simpler TRT adjuncts. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

Synthetic melanocortin receptor agonist (MC1R-MC5R); activates MC4R for erectile function/libido; MC1R for melanogenesis; MC3R for appetite suppression

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide that activates melanocortin receptors (MC1R, MC4R) involved in pigmentation, sexual arousal, and appetite regulation. By agonizing MC4R receptors in the central nervous system, melanotan II promotes erectile function and sexual arousal through a centrally mediated pathway, distinct from the peripheral vasodilatory mechanism of PDE5 inhibitors. An early randomized controlled trial demonstrated significant improvements in erectile function and sexual desire in men with organic erectile dysfunction, and subsequent reviews have characterized the melanocortin receptor class as a pharmacological target for sexual dysfunction. Melanotan II is not approved by the FDA or any major regulatory agency for any indication; it is a research compound associated with significant off-target effects, and a related compound (bremelanotide, marketed as PT-141) holds FDA approval for hypoactive sexual desire disorder in pre-menopausal women. Melanotan II vs PT-141: bremelanotide (PT-141) was developed directly from the melanotan II research program as a cleaner successor compound. PT-141 was designed to retain the MC4R-mediated sexual response effects while reducing the tanning (MC1R) and nausea side effects that characterize melanotan II. The key practical distinction is that PT-141 has completed Phase 3 trials and holds FDA approval, while melanotan II remains an unapproved research compound. Melanotan II is associated with more pronounced side effects than its successor — including facial flushing, nausea, spontaneous erections, and significant skin pigmentation from MC1R activation — which contributed to its replacement by the more selective bremelanotide in clinical development. Research doses in published studies have used subcutaneous administration in the range of 0.5–1 mg per dose; the side effect profile is dose-dependent, with nausea being the most commonly reported adverse event. Melanotan II has no approved clinical use in any jurisdiction; individuals interested in melanocortin-based sexual health compounds are better served by consulting providers offering FDA-approved PT-141 (bremelanotide), listed in the PeptideBase directory.